Neuberg Diagnostics to invest Rs 300 cr for expansion

Mumbai: Neuberg Diagnostics, an alliance of five leading pathology laboratories from India, South Africa and the UAE, is planning to invest Rs 300 crore in India, the Middle East and Africa as part of its expansion plans.

“We are looking at investing another Rs 300 crore for expansion plans in the coming years, which will be funded through internal accruals,” Neuberg Diagnostics chairman GSK Velu told here.

The company having focus on new generation technologies in the diagnostics space, according to Velu has already invested Rs 450 crore in acquiring laboratories in India and abroad and upgrading them.

Neuberg at present has 50 labs and 500 centres in the south and west India, and plans to increase the total count to 150 labs and 1,000 centres in the next three years.

“We will have three world class global reference laboratories located in Bengaluru, Ahmedabad, and Durban (South Africa) carrying out advanced range of testing using new generation in vitro diagnostics techniques,” he said.

The company sees faster growth in African markets and plans to enter into Kenya, Uganda, Nigeria, Tanzania and Ethiopian markets.

According to Velu, new generation technologies like genomics, metabolomics and proteomics that provide accurate diagnosis and also combination diagnostics, where hospitals, pharma companies and pathologists work together, is the future of the diagnostics industry.

“India is lagging behind in terms of technology and we wants to focus in those areas,” he said.

An alliance of five top laboratories like Anand Diagnostic Laboratory, Supratech Micropath, Ehrlich lab, Global labs and Minerva Labs, the company plans to have three infrastructure models global centre of excellence, regional reference centres and satellite centres.

It also wants to establish research centres in the US and European markets, to get access to latest technologies and bring it to India, according to Velu.

“Talks are on with some universities and small labs in the regions,” he said.

The company, which is growing at a compounded annual growth rate of 15 per cent, clocked an consolidated revenue of Rs 400 crore last year and hopes to cross Rs 1,000-crore mark by 2021-22.

  • Related Posts

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    AiMeD welcomes the move long overdue to boost India’s Regulatory Framework New Delhi: 21 Drug Inspectors have been promoted to Assistant Drugs Controllers (India) under CDSCO. It was long unmet…

    Yashoda Medicity lifts Benchmark in Critical Care to New High

    With the introduction of North India’s first Advanced VitalGo Total Lift Bed Technology Ghaziabad/ New Delhi: In an ideal hospital, critical care is most paramount and it is also the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

    Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

    ‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

    ‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses